Chromos and Genitope Corporation sign cell line engineering contract
Chromos Molecular Systems Inc. announced that it has entered into a cell line engineering service agreement with Genitope Corporation to develop a cell line using Chromos' ACE System for potential use in the clinical and commercial manufacture of a biopharmaceutical product.
Under the agreement, Chromos will engineer cell lines for the expression of a monoclonal antibody for Genitope using the ACE System. The financial details of the agreement were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Cosmo holds 94.7% of BioXell voting rights and shares
Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence
Timing is key for bacteria surviving antibiotics
Macrovipera_lebetina_turanica

Virus multiplication in 3D

Coffee only wakes you up if you rarely drink it - What is the ideal way to consume coffee?
